In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains
In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains
复制标题
DOI：
10.1016/j.jgar.2017.05.022
复制
发表时间：
2017-09-01
影响因子：
4.6
通讯作者：
Derbentli, Sengul
中科院分区：
文献类型：
--
作者：
Aktas, Gulseren;Derbentli, Sengul
目的：尽管在过去几年中已经引入了旨在治疗具有有限治疗选择的感染的新的抗微生物剂，但是耐药革兰氏阳性球菌继续出现和传播。达托霉素是一种环脂肽抗生素，对广谱革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））具有快速杀菌活性。有时联合使用抗生素，试图预防或延迟病原生物体耐药亚群的体内出现。本研究的目的是评估达托霉素与利福平、庆大霉素、磷霉素和夫西地酸组合对MRSA菌株的体外活性。所有抗生素的最低抑菌浓度采用微量肉汤稀释法测定。采用微量肉汤棋盘法评价抗生素联合用药的体外抗菌活性。结果：根据MIC值，达托霉素敏感率为100%，利福平敏感率为16%，庆大霉素敏感率为20%，磷霉素敏感率为44%，夫西地酸敏感率为72%。达托霉素与利福平、庆大霉素、磷霉素和夫西地酸的联合增效作用分别为12%、68%、100%和16%。结论：达托霉素与磷霉素联合治疗MRSA感染可能是一种有前途的替代疗法。(C)2017年国际感染和癌症化疗学会。由爱思唯尔有限公司出版。保留所有权利。
Objectives: Although new antimicrobial agents designed to treat infections with limited therapeutic options have been introduced in the past few years, resistant Gram positive cocci have continued to emerge and spread. Daptomycin is a cyclic lipopeptide antibiotic that has rapid bactericidal activity against broad spectrum of Gram positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). Antibiotics are sometimes used in combination in an attempt to prevent or delay the in vivo emergence of drug-resistant subpopulations of pathogenic organisms. The aim of the study was to evaluate in vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin, and fusidic acid against MRSA strains.Methods: In total, 25 strains were tested. The minimum inhibitory concentrations of all antibiotics were determined using a microbroth dilution assay. The in vitro activities of antibiotics in combination were assessed using the microbroth checkerboard technique. With this method, the fractional inhibitory concentration index was interpreted as follows: synergism 0.5- 4.Results: According to the MIC values, all strains (100%) were susceptible to daptomycin, 16% (4/25) to rifampicin, 20% (5/25) to gentamicin, 44% (11/25) to fosfomycin, and 72% (18/25) to fusidic acid. Synergistic interaction of daptomycin in combinations with rifampicin, gentamicin, fosfomycin, and fusidic acid were found as 12%, 68%, 100% and 16%, respectively. No antagonism was observed.Conclusion: The combination of daptomycin with fosfomycin may be a promising alternative therapy of MRSA infections. (C) 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.